{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T09:13:59Z","timestamp":1794129239417,"version":"4.8.0"},"reference-count":162,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Thematic Excellence Program"},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"crossref"}]},{"name":"PANDORA","award":["CRC1181"],"award-info":[{"award-number":["CRC1181"]}],"id":[{"id":"https:\/\/ror.org\/038m7b802","id-type":"ROR","asserted-by":"crossref"}]},{"name":"PANDORA","award":["CRC1483"],"award-info":[{"award-number":["CRC1483"]}],"id":[{"id":"https:\/\/ror.org\/038m7b802","id-type":"ROR","asserted-by":"crossref"}]},{"name":"PANDORA","award":["FOR2886"],"award-info":[{"award-number":["FOR2886"]}],"id":[{"id":"https:\/\/ror.org\/038m7b802","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"name":"T\u00e9mater\u00fcleti Kiv\u00e1l\u00f3s\u00e1gi Program","award":["TKP2021-EGA-29"],"award-info":[{"award-number":["TKP2021-EGA-29"]}]},{"name":"DFG","award":["FOR2886"],"award-info":[{"award-number":["FOR2886"]}]},{"name":"DFG","award":["GK2599"],"award-info":[{"award-number":["GK2599"]}]},{"name":"DFG","award":["Mi939\/6-1"],"award-info":[{"award-number":["Mi939\/6-1"]}]},{"name":"ERC"},{"name":"Ministry for Innovation and Technology in Hungary","id":[{"id":"https:\/\/ror.org\/02ey3ab96","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1136\/ard-2024-225727","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T13:15:29Z","timestamp":1716383729000},"page":"1409-1420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":117,"title":["B-cell depletion in autoimmune diseases"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8740-9615","authenticated-orcid":false,"given":"Georg","family":"Schett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1198-3228","authenticated-orcid":false,"given":"Gy\u00f6rgy","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Kr\u00f6nke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Mielenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2024-225727_bib1","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.4049\/jimmunol.178.10.6092","article-title":"Distinct effector cytokine profiles of memory and naive human B-cell subsets and implication in multiple sclerosis","volume":"178","author":"Duddy","year":"2007","journal-title":"J Immunol"},{"key":"10.1136\/ard-2024-225727_bib2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.immuni.2008.05.009","article-title":"Generation of T follicular helper cells is mediated by Interleukin\u201021 but independent of T helper 1, 2, or 17 cell lineages","volume":"29","author":"Nurieva","year":"2008","journal-title":"Immunity"},{"key":"10.1136\/ard-2024-225727_bib3","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1084\/jem.20111504","article-title":"B and T-cells collaborate in antiviral responses via IL\u20106, IL\u201021, and transcriptional activator and coactivator, OCT2 and OBF\u20101","volume":"209","author":"Karnowski","year":"2012","journal-title":"J Exp Med"},{"key":"10.1136\/ard-2024-225727_bib4","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.immuni.2015.04.005","article-title":"Regulatory B-cells: origin, phenotype, and function","volume":"42","author":"Rosser","year":"2015","journal-title":"Immunity"},{"key":"10.1136\/ard-2024-225727_bib5","first-page":"82","article-title":"Specific B lymphocytes efficiently pick up, process and present antigen to T-cells","author":"Lanzavecchia","year":"1985","journal-title":"Behring Inst Mitt"},{"key":"10.1136\/ard-2024-225727_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/369147a0","article-title":"Antigen processing and class II MHC peptide\u2010loading compartments in human B\u2010Lymphoblastoid cells","volume":"369","author":"West","year":"1994","journal-title":"Nature"},{"key":"10.1136\/ard-2024-225727_bib7","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.4049\/jimmunol.1301284","article-title":"B-cell antigen presentation in the initiation of follicular helper T-cell and germinal center differentiation","volume":"192","author":"Barnett","year":"2014","journal-title":"J Immunol"},{"key":"10.1136\/ard-2024-225727_bib8","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1182\/blood-2004-09-3740","article-title":"B-cell Kinetics in humans: rapid turnover of peripheral blood memory cells","volume":"105","author":"Macallan","year":"2005","journal-title":"Blood"},{"key":"10.1136\/ard-2024-225727_bib9","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1084\/jem.184.6.2217","article-title":"Ordering of human bone marrow B lymphocyte precursors by single-cell polymerase chain reaction analyses of the rearrangement status of the immunoglobulin H and L chain gene Loci","volume":"184","author":"Ghia","year":"1996","journal-title":"J Exp Med"},{"key":"10.1136\/ard-2024-225727_bib10","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2008-02-078071","article-title":"B lymphocytes: how they develop and function","volume":"112","author":"LeBien","year":"2008","journal-title":"Blood"},{"key":"10.1136\/ard-2024-225727_bib11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.smim.2005.11.002","article-title":"Initiation of pre-B-cell receptor signaling: common and distinctive features in human and Mouse","volume":"18","author":"Espeli","year":"2006","journal-title":"Semin Immunol"},{"key":"10.1136\/ard-2024-225727_bib12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1182\/blood-2009-07-234799","article-title":"Differential expression of Cd21 identifies developmentally and functionally distinct Subsets of human transitional B-cells","volume":"115","author":"Suryani","year":"2010","journal-title":"Blood"},{"key":"10.1136\/ard-2024-225727_bib13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nri.2017.19","article-title":"Mechanisms of central tolerance for B cells","volume":"17","author":"Nemazee","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1136\/ard-2024-225727_bib14","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.1086907","article-title":"Predominant autoantibody production by early human B cell precursors","volume":"301","author":"Wardemann","year":"2003","journal-title":"Science"},{"key":"10.1136\/ard-2024-225727_bib15","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1172\/JCI84645","article-title":"Decreased somatic hypermutation induces an impaired peripheral B cell tolerance checkpoint","volume":"126","author":"Cantaert","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1136\/ard-2024-225727_bib16","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20202001","article-title":"Human marginal zone B-cell development from early T2 progenitors","volume":"218","author":"Tull","year":"2021","journal-title":"J Exp Med"},{"key":"10.1136\/ard-2024-225727_bib17","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201952","article-title":"Systematic memory B-cell archiving and random display shape the human splenic marginal zone throughout life","volume":"218","author":"Kibler","year":"2021","journal-title":"J Exp Med"},{"key":"10.1136\/ard-2024-225727_bib18","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1084\/jem.188.9.1679","article-title":"Human immunoglobulin (Ig)M+Igd+ peripheral blood B-cells expressing the CD27 cell surface antigen carry Somatically Mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B-cells","volume":"188","author":"Klein","year":"1998","journal-title":"J Exp Med"},{"key":"10.1136\/ard-2024-225727_bib19","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.188.9.1691","article-title":"Identification of functional human splenic memory B-cells by expression of CD148 and CD27","volume":"188","author":"Tangye","year":"1998","journal-title":"J Exp Med"},{"key":"10.1136\/ard-2024-225727_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abm9060","article-title":"Two subsets of human marginal zone B-cells resolved by global analysis of lymphoid tissues and blood","volume":"7","author":"Siu","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1136\/ard-2024-225727_bib21","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.immuni.2018.08.015","article-title":"Distinct Effector B-cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus","volume":"49","author":"Jenks","year":"2018","journal-title":"Immunity"},{"key":"10.1136\/ard-2024-225727_bib22","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/ni.3175","article-title":"Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus","volume":"16","author":"Tipton","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1136\/ard-2024-225727_bib23","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.immuni.2020.11.006","article-title":"Germinal center and extrafollicular B-cell responses in vaccination, immunity, and autoimmunity","volume":"53","author":"Elsner","year":"2020","journal-title":"Immunity"},{"key":"10.1136\/ard-2024-225727_bib24","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar3909","article-title":"Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity","volume":"14 Suppl 5","author":"Mei","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2024-225727_bib25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.imlet.2023.03.003","article-title":"Igd-Cd27- doUble negative (DN) B-cells: origins and functions in health and disease","volume":"255","author":"Beckers","year":"2023","journal-title":"Immunology Letters"},{"key":"10.1136\/ard-2024-225727_bib26","doi-asserted-by":"crossref","first-page":"e17341","DOI":"10.15252\/emmm.202217341","article-title":"Functions of double-negative B-cells in autoimmune diseases, infections, and cancers","volume":"15","author":"Chung","year":"2023","journal-title":"EMBO Mol Med"},{"key":"10.1136\/ard-2024-225727_bib27","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1002\/art.23498","article-title":"Activated memory B-cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of Cd27, Igd, and Cd95","volume":"58","author":"Jacobi","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2024-225727_bib28","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41584-020-00544-4","article-title":"Toll-like receptor signalling in B-cells during systemic lupus erythematosus","volume":"17","author":"Fillatreau","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2024-225727_bib29","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41586-022-04642-z","article-title":"Tlr7 gain-of-function genetic variation causes human lupus","volume":"605","author":"Brown","year":"2022","journal-title":"Nature"},{"key":"10.1136\/ard-2024-225727_bib30","doi-asserted-by":"crossref","first-page":"1021370","DOI":"10.3389\/fimmu.2022.1021370","article-title":"The extrafollicular response is sufficient to drive initiation of autoimmunity and early disease hallmarks of lupus","volume":"13","author":"Voss","year":"2022","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2024-225727_bib31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1146\/annurev.iy.12.040194.001001","article-title":"Germinal centers","volume":"12","author":"MacLennan","year":"1994","journal-title":"Annu Rev Immunol"},{"key":"10.1136\/ard-2024-225727_bib32","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0092-8674(81)90325-1","article-title":"The role of DNA rearrangement and alternative RNA processing in the expression of immunoglobulin delta genes","volume":"24","author":"Maki","year":"1981","journal-title":"Cell"},{"key":"10.1136\/ard-2024-225727_bib33","first-page":"1311","article-title":"Tissue cytokine patterns distinguish variants of rheumatoid synovitis","volume":"151","author":"Klimiuk","year":"1997","journal-title":"Am J Pathol"},{"key":"10.1136\/ard-2024-225727_bib34","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/acr.20441","article-title":"Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring","volume":"63","author":"Hsieh","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2024-225727_bib35","unstructured":"Anaya JM, Talal N,. Sj\u00f6gren's syndrome and connective tissue diseases associated with other immunological diseases. In: Koopman W, ed. Arthritis and Allied Conditions: a Textbook of Rheumatology, 13e. Philadelphia, PA: Williams & Wilkins, 1997: 1561\u201380."},{"key":"10.1136\/ard-2024-225727_bib36","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/brain\/awm038","article-title":"Meningeal B\u2010cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology","volume":"130","author":"Magliozzi","year":"2007","journal-title":"Brain"},{"key":"10.1136\/ard-2024-225727_bib37","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/jcp.30760","article-title":"Effect of Cd38 on B-cell function and its role in the diagnosis and treatment of B-cell-related diseases","volume":"237","author":"Zeng","year":"2022","journal-title":"J Cell Physiol"},{"key":"10.1136\/ard-2024-225727_bib38","doi-asserted-by":"crossref","first-page":"101726","DOI":"10.1016\/j.trim.2022.101726","article-title":"Bone marrow derived long-lived plasma cell phenotypes are heterogeneous and can change in culture","volume":"75","author":"Mujtahedi","year":"2022","journal-title":"Transpl Immunol"},{"key":"10.1136\/ard-2024-225727_bib39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cyto.b.21265","article-title":"Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma","volume":"90","author":"Flores-Montero","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1136\/ard-2024-225727_bib40","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1056\/NEJMoa066092","article-title":"Duration of humoral immunity to common viral and vaccine antigens","volume":"357","author":"Amanna","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225727_bib41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/40540","article-title":"Lifetime of plasma cells in the bone marrow","volume":"388","author":"Manz","year":"1997","journal-title":"Nature"},{"key":"10.1136\/ard-2024-225727_bib42","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.4049\/jimmunol.171.10.4969","article-title":"Cutting edge: long-term B-cell memory in humans after smallpox vaccination","volume":"171","author":"Crotty","year":"2003","journal-title":"J Immunol"},{"key":"10.1136\/ard-2024-225727_bib43","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/imr.12656","article-title":"Immunological memories of the bone marrow","volume":"283","author":"Chang","year":"2018","journal-title":"Immunol Rev"},{"key":"10.1136\/ard-2024-225727_bib44","doi-asserted-by":"crossref","first-page":"11876","DOI":"10.1038\/s41598-022-15293-5","article-title":"Integrated single cell and spatial transcriptomics reveal autoreactive differentiated B-cells in joints of early rheumatoid arthritis","volume":"12","author":"Hardt","year":"2022","journal-title":"Sci Rep"},{"key":"10.1136\/ard-2024-225727_bib45","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.imlet.2023.06.005","article-title":"Targeting plasma cells in systemic autoimmune rheumatic diseases - promises and pitfalls","volume":"260","author":"Steinmetz","year":"2023","journal-title":"Immunol Lett"},{"key":"10.1136\/ard-2024-225727_bib46","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41584-020-0480-7","article-title":"New insights into the role of antinuclear antibodies in systemic lupus erythematosus","volume":"16","author":"Pisetsky","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2024-225727_bib47","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1002\/art.21890","article-title":"Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies","volume":"54","author":"Hua","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2024-225727_bib48","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/annrheumdis-2021-221662","article-title":"Anti-RNP antibodies are associated with the interferon gene signature but not decreased complement levels in SLE","volume":"81","author":"Hubbard","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225727_bib49","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1177\/0961203396005001031","article-title":"Anti-Malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development","volume":"5 Suppl 1","author":"Fox","year":"1996","journal-title":"Lupus"},{"key":"10.1136\/ard-2024-225727_bib50","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/jpet.120.000275","article-title":"Discovery of M5049: a novel selective toll-like receptor 7\/8 inhibitor for treatment of autoimmunity","volume":"376","author":"Vlach","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1136\/ard-2024-225727_bib51","doi-asserted-by":"crossref","first-page":"73ra20","DOI":"10.1126\/scitranslmed.3001201","article-title":"Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus","volume":"3","author":"Garcia-Romo","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1136\/ard-2024-225727_bib52","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41591-018-0254-9","article-title":"A Cd4+ T-Cell population expanded in lupus blood provides B-cell help through Interleukin-10 and succinate","volume":"25","author":"Caielli","year":"2019","journal-title":"Nat Med"},{"key":"10.1136\/ard-2024-225727_bib53","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225727_bib54","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/imr.12810","article-title":"BAFF inhibition in SLE-is tolerance restored","volume":"292","author":"Jackson","year":"2019","journal-title":"Immunol Rev"},{"key":"10.1136\/ard-2024-225727_bib55","doi-asserted-by":"crossref","first-page":"102668","DOI":"10.1016\/j.autrev.2020.102668","article-title":"Phoenix from the flames: rediscovering the role of the Cd40-Cd40L pathway in systemic lupus erythematosus and lupus nephritis","volume":"19","author":"Ramanujam","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard-2024-225727_bib56","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/art.41811","article-title":"Efficacy, safety, and pharmacodynamic effects of the Bruton's tyrosine kinase inhibitor Fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial","volume":"73","author":"Isenberg","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-225727_bib57","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1901981","article-title":"Evobrutinib phase 2 study group. placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis","volume":"380","author":"Montalban","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225727_bib58","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1474-4422(21)00237-4","article-title":"Tolebrutinib phase 2B study group. safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2B, randomised, double-blind, placebo-controlled trial","volume":"20","author":"Reich","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1136\/ard-2024-225727_bib59","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.immuni.2006.08.010","article-title":"Type I interferon in systemic lupus erythematosus and other autoimmune diseases","volume":"25","author":"Banchereau","year":"2006","journal-title":"Immunity"},{"key":"10.1136\/ard-2024-225727_bib60","doi-asserted-by":"crossref","first-page":"e207937","DOI":"10.1212\/WNL.0000000000207937","article-title":"Safety and efficacy of nipocalimab in patients with generalized myasthenia gravis: results from the randomized phase 2 vivacity-MG study","volume":"102","author":"Antozzi","year":"2024","journal-title":"Neurology"},{"key":"10.1136\/ard-2024-225727_bib61","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti\u2010CD20 monoclonal antibody and polymorphism in IgG FC receptor Fcgamma Riiia gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"10.1136\/ard-2024-225727_bib62","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor Polymorphisms independently predict response to Rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1136\/ard-2024-225727_bib63","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1200\/JCO.2005.06.059","article-title":"Polymorphisms in Fcgammariiia (CD16) receptor expression are associated with clinical response to Rituximab in Waldenstrom's Macroglobulinemia","volume":"23","author":"Treon","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1136\/ard-2024-225727_bib64","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.4049\/jimmunol.125.4.1678","article-title":"Characterization of a human B lymphocyte\u2010specific antigen","volume":"125","author":"Stashenko","year":"1980","journal-title":"J Immunol"},{"key":"10.1136\/ard-2024-225727_bib65","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","article-title":"Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes","volume":"40","author":"Edwards","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-225727_bib66","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/art.10467","article-title":"Efficacy of selective B-cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B-cells","volume":"46","author":"De Vita","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2024-225727_bib67","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/ard.61.10.883","article-title":"Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion","volume":"61","author":"Leandro","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225727_bib68","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of Rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2024-225727_bib69","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2024-225727_bib70","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3899\/jrheum.090442","article-title":"Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial","volume":"37","author":"Mease","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2024-225727_bib71","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/ard.2009.119933","volume":"69","author":"Emery","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225727_bib72","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/rheumatology\/keq116","article-title":"Efficacy and safety of various repeat treatment dosing regimens of Rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR)","volume":"49","author":"Rubbert-Roth","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-225727_bib73","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/art.30194","article-title":"Evaluation of the safety of Rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial","volume":"63","author":"Greenwald","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2024-225727_bib74","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/ard.2010.137703","article-title":"Inhibition of joint damage and improved clinical outcomes with Rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial","volume":"70","author":"Tak","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225727_bib75","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA\u2010associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225727_bib76","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA\u2010associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225727_bib77","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"French vasculitis study group. comparison of individually tailored versus fixed-schedule Rituximab regimen to maintain ANCA-associated vasculitis remission: results of a Multicentre","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225727_bib78","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus mycophenolate mofetil in patients with Pemphigus Vulgaris","volume":"384","author":"Werth","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225727_bib79","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of Rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1136\/ard-2024-225727_bib80","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B\u2010cell depletion withrituximab in relapsing\u2010remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225727_bib81","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double blind placebo\u2010controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1136\/ard-2024-225727_bib82","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/annrheumdis-2014-206605","article-title":"Rituximab for IgG4-related disease: a prospective, open-label trial","volume":"74","author":"Carruthers","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225727_bib83","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.autrev.2014.11.014","article-title":"Efficacy and safety of Rituximab in autoimmune hemolytic anemia: a meta-analysis of 21 studies","volume":"14","author":"Reynaud","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard-2024-225727_bib84","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"RECITAL investigators. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2B trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1136\/ard-2024-225727_bib85","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"LUNAR investigator group. efficacy and safety of Rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2024-225727_bib86","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of Rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of Rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis & Rheumatism"},{"key":"10.1136\/ard-2024-225727_bib87","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.41466","article-title":"Phase II randomized trial of Rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis","volume":"73","author":"Atisha-Fregoso","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-225727_bib88","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/acr.22921","article-title":"Use of Rituximab in systemic lupus erythematosus: a single center experience over 14 years","volume":"69","author":"Aguiar","year":"2017","journal-title":"Arthr Care & Res"},{"key":"10.1136\/ard-2024-225727_bib89","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/art.27541","article-title":"Safety and efficacy of Rituximab in systemic lupus erythematosus: results from 136 patients from the French Autoimmunity and Rituximab Registry","volume":"62","author":"Terrier","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2024-225727_bib90","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/rheumatology\/kex395","article-title":"Short-term efficacy and safety of Rituximab therapy in refractory systemic lupus erythematosus: results from the British isles lupus assessment group Biologics register","volume":"57","author":"McCarthy","year":"2018","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2024-225727_bib91","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","article-title":"Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with Rituximab and mycophenolate mofetil but no oral steroids","volume":"72","author":"Condon","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225727_bib92","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.autrev.2011.10.009","article-title":"Efficacy of Rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts","volume":"11","author":"D\u00edaz-Lagares","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard-2024-225727_bib93","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/rheumatology\/kes348","article-title":"Long-term follow-up in lupus nephritis patients treated with Rituximab\u2013clinical and histopathological response","volume":"52","author":"J\u00f3nsd\u00f3ttir","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-225727_bib94","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225727_bib95","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2024-225727_bib96","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2024-225727_bib97","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/rheumatology\/ker305","article-title":"Efficacy and safety of Rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry","volume":"50","author":"Couderc","year":"2011","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2024-225727_bib98","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized controlled trial of Rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sj\u00f6gren's syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-225727_bib99","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sj\u00f6gren syndrome with Rituximab: results of a randomised, double-blind, placebo-controlled pilot study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225727_bib100","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/art.37850","article-title":"Autoimmunity centers of excellence. Rituximab therapy for primary Sj\u00f6gren's syndrome: an open-label clinical trial and mechanistic analysis","volume":"65","author":"St Clair","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2024-225727_bib101","doi-asserted-by":"crossref","first-page":"R172","DOI":"10.1186\/ar4359","article-title":"Efficacy and safety of Rituximab treatment in early primary Sj\u00f6gren's syndrome: a prospective, multi-center, follow-up study","volume":"15","author":"Carubbi","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2024-225727_bib102","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1016\/S2665-9913(22)00131-X","article-title":"Safety and efficacy of Rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial","volume":"4","author":"Ebata","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2024-225727_bib103","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","article-title":"Outcomes of patients with systemic sclerosis treated with Rituximab in contemporary practice: a prospective cohort study","volume":"78","author":"Elhai","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225727_bib104","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/annrheumdis-2011-200706","article-title":"Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial","volume":"71","author":"Stohl","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225727_bib105","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/art.33317","article-title":"Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial","volume":"64","author":"Rigby","year":"2012","journal-title":"Arthri & Rheum"},{"key":"10.1136\/ard-2024-225727_bib106","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/art.33353","article-title":"Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty\u2010eight\u2010week randomized, double\u2010blind, placebo\u2010controlled, parallel\u2010group phase III trial","volume":"64","author":"Tak","year":"2012","journal-title":"Arthri & Rheum"},{"key":"10.1136\/ard-2024-225727_bib107","doi-asserted-by":"crossref","first-page":"e87379","DOI":"10.1371\/journal.pone.0087379","article-title":"Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program","volume":"9","author":"Emery","year":"2014","journal-title":"PLoS One"},{"key":"10.1136\/ard-2024-225727_bib108","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.38037","article-title":"Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study","volume":"65","author":"Mysler","year":"2013","journal-title":"Arthri Rheum"},{"key":"10.1136\/ard-2024-225727_bib109","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1A in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225727_bib110","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225727_bib111","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1182\/blood-2013-05-504043","article-title":"Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than Rituximab","volume":"122","author":"Golay","year":"2013","journal-title":"Blood"},{"key":"10.1136\/ard-2024-225727_bib112","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225727_bib113","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225727_bib114","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus teriflunomide in relapsing multiple sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225727_bib115","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-momentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1136\/ard-2024-225727_bib116","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1002\/art.42652","article-title":"Obexelimab in systemic lupus erythematosus with exploration of response based on gene pathway co-expression patterns: a double-blind, randomized, placebo-controlled, phase 2 trial","volume":"75","author":"Merrill","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-225727_bib117","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/art.39856","article-title":"Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials","volume":"69","author":"Clowse","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-225727_bib118","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of primary Sj\u00f6gren's syndrome with Ianalumab (Vay736) targeting B-cells by BAFF receptor blockade coupled with enhanced, antibody-dependenT-cellular cytotoxicity","volume":"78","author":"D\u00f6rner","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225727_bib119","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous Ianalumab (Vay736) in patients with primary Sj\u00f6gren's syndrome: a randomised, double-blind, placebo-controlled, phase 2B dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"key":"10.1136\/ard-2024-225727_bib120","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2B, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225727_bib121","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/art.40360","article-title":"Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study","volume":"70","author":"Merrill","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2024-225727_bib122","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1474-4422(14)70028-6","article-title":"Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"13","author":"Kappos","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1136\/ard-2024-225727_bib123","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225727_bib124","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1093\/rheumatology\/keac393","article-title":"Effective and safe treatment of anti-CD38 therapy in systemic lupus erythematosus\u2013associated refractory cerebral vasculitis induces immune tolerance","volume":"62","author":"Yalcin Mutlu","year":"2023","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2024-225727_bib125","doi-asserted-by":"crossref","first-page":"645478","DOI":"10.3389\/fimmu.2021.645478","article-title":"Restoration of NK cell cytotoxic function with elotuzumab and daratumumab promotes elimination of circulating plasma cells in patients with SLE","volume":"12","author":"Humbel","year":"2021","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2024-225727_bib126","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of Hypogammaglobulinemia in patients receiving Rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1136\/ard-2024-225727_bib127","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1002\/art.30466","article-title":"B-cell biomarkers of Rituximab responses in systemic lupus erythematosus","volume":"63","author":"Vital","year":"2011","journal-title":"Arthritis & Rheumatism"},{"key":"10.1136\/ard-2024-225727_bib128","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/rheumatology\/ket004","article-title":"Serum Rituximab levels and efficiency of B-cell depletion: differences between patients with rheumatoid arthritis and systemic lupus erythematosus","volume":"52","author":"Reddy","year":"2013","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2024-225727_bib129","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.2215\/CJN.01070118","article-title":"Peripheral blood B-cell depletion after Rituximab and complete response in lupus nephritis","volume":"13","author":"Gomez Mendez","year":"2018","journal-title":"CJASN"},{"key":"10.1136\/ard-2024-225727_bib130","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/art.23473","article-title":"Anti\u2010Cd20 therapy in patients with rheumatoid arthritis: predictors of response and B-cell subset regeneration after repeated treatment","volume":"58","author":"Roll","year":"2008","journal-title":"Arthri Rheum"},{"key":"10.1136\/ard-2024-225727_bib131","doi-asserted-by":"crossref","first-page":"e80533","DOI":"10.1371\/journal.pone.0080533","article-title":"Subcutaneous versus intravenous administration of Rituximab: Pharmaco-Kinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys","volume":"8","author":"Mao","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1136\/ard-2024-225727_bib132","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.4049\/jimmunol.179.5.3351","article-title":"Depletion of B-cells in murine lupus: efficacy and resistance","volume":"179","author":"Ahuja","year":"2007","journal-title":"J Immunol"},{"key":"10.1136\/ard-2024-225727_bib133","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/1529-0131(200201)46:1<191::AID-ART10027>3.0.CO;2-K","article-title":"Impaired uptake of apoptotic cells into Tingible body Macrophages in germinal centers of patients with systemic lupus erythematosus","volume":"46","author":"Baumann","year":"2002","journal-title":"Arthri Rheum"},{"key":"10.1136\/ard-2024-225727_bib134","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ajt.12220","article-title":"A single dose of Rituximab does not deplete B-cells in secondary Lymphoid organs but alters phenotype and function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1136\/ard-2024-225727_bib135","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/ard.2009.109041","article-title":"Clinical response, pharmacokinetics, development of human anti-chimeric antibodies, and Synovial tissue response to Rituximab treatment in patients with rheumatoid arthritis","volume":"69","author":"Thurlings","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225727_bib136","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/ard.2007.074229","article-title":"Assessment of Rituximab's immunomodulatory Synovial effects (ARISE trial). 1: clinical and Synovial biomarker results","volume":"67","author":"Kavanaugh","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225727_bib137","doi-asserted-by":"crossref","first-page":"R123","DOI":"10.1186\/ar2789","article-title":"Short- and long-term effects of anti-CD20 treatment on B-cell ontogeny in bone marrow of patients with rheumatoid arthritis","volume":"11","author":"Rehnberg","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2024-225727_bib138","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1002\/art.22810","article-title":"Delayed memory B-cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B-cell depletion therapy","volume":"56","author":"Anolik","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2024-225727_bib139","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1158\/2326-6066.CIR-15-0048","article-title":"CAR-T-cells inflict sequential killing of multiple tumor target cells","volume":"3","author":"Davenport","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1136\/ard-2024-225727_bib140","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T-cells in chronic Lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225727_bib141","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T-cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225727_bib142","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T-cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1136\/ard-2024-225727_bib143","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","article-title":"Anti-CD19 CAR T-cells for refractory myasthenia gravis","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1136\/ard-2024-225727_bib144","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T-cells in refractory Antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"key":"10.1136\/ard-2024-225727_bib145","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"Et al CD19-targeting CAR T-cells for myositis and interstitial lung disease associated with anti-synthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"10.1136\/ard-2024-225727_bib146","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSC) using CD19-targeted CAR-T-cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225727_bib147","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/ard-2023-225174","article-title":"Third-generation CD19.CAR-T-cell-containing combination therapy in Scl70+ systemic sclerosis","volume":"83","author":"Merkt","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225727_bib148","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2315990121","article-title":"Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T-cell therapy","volume":"121","author":"Qin","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1136\/ard-2024-225727_bib149","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"Et al.Cd19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225727_bib150","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard-2024-225638","article-title":"Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease","volume":"83","author":"Daamen","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-225727_bib151","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.4049\/jimmunol.1402424","article-title":"Bone marrow plasma cells are a primary source of serum HIV-1-specific antibodies in chronically infected individuals","volume":"194","author":"Montezuma-Rusca","year":"2015","journal-title":"J Immunol"},{"key":"10.1136\/ard-2024-225727_bib152","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/blood-2019-03-900928","article-title":"CAR-T efficacy: is conditioning the key","volume":"133","author":"Neelapu","year":"2019","journal-title":"Blood"},{"key":"10.1136\/ard-2024-225727_bib153","first-page":"352","article-title":"A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures","volume":"26","author":"Adams","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2024-225727_bib154","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/rheumatology\/kem001","article-title":"Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis","volume":"46","author":"Illei","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2024-225727_bib155","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/art.42784","article-title":"CD19 Chimeric antigen receptor T-cell treatment: unraveling the role of B-cells in systemic lupus erythematosus","volume":"76","author":"Taubmann","year":"2024","journal-title":"Arthri Rheum"},{"key":"10.1136\/ard-2024-225727_bib156","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary cancers after chimeric antigen receptor T-cell therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2024-225727_bib157","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.2020010497","article-title":"The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma","volume":"138","author":"Chihara","year":"2021","journal-title":"Blood"},{"key":"10.1136\/ard-2024-225727_bib158","doi-asserted-by":"crossref","first-page":"S853","DOI":"10.1016\/j.jval.2019.09.2396","article-title":"Incidence and prevalence of T-cell lymphoma in the EMA membre States: methodology for estimation in rare Malignacies of CTCL and PTCL","volume":"22","author":"Zhang","year":"2019","journal-title":"Value in Health"},{"key":"10.1136\/ard-2024-225727_bib159","unstructured":"Liu A,. FDA investigates \u201eserious risk\u201c of secondary cancer following CAR T-cell treatment. Fierce Pharama; 2023. Available: https:\/\/www.fiercepharma.com\/pharma\/fda-investigates-serious-risk-secondary-cancer-following-car-t-therapy-treatment."},{"key":"10.1136\/ard-2024-225727_bib160","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T-cell lymphoma and secondary primary malignancy risk after commercial CAR T-cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat Med"},{"key":"10.1136\/ard-2024-225727_bib161","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B-cell depletion by CD19-targeted CAR T-cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1136\/ard-2024-225727_bib162","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1056\/NEJMe2400203","article-title":"CAR T-cells - a new horizon for autoimmunity","volume":"390","author":"Isaacs","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724665349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724665349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2024-225727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T03:17:16Z","timestamp":1735960636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724665349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":162,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0003496724665349"],"URL":"https:\/\/doi.org\/10.1136\/ard-2024-225727","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B-cell depletion in autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2024-225727","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 \u00a9 Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by Elsevier Inc on behalf of EULAR. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}